Rifaximin Amorphous Solid Dispersion for Sickle Cell Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for sickle cell disease (SCD) are inadequate in managing recurrent painful vaso-occlusive crises and improving quality of life, as they often require high dosages of medications with significant systemic exposure and limited efficacy in reducing elevated circulating aged neutrophils.
Innovation Solution
The use of compositions comprising rifaximin, hydrogenated castor oil, and additional solubilizing excipients to enhance gastrointestinal luminal solubility of rifaximin, thereby reducing systemic exposure and effectively lowering circulating aged neutrophils, thereby alleviating vaso-occlusive crises with a substantially reduced dosage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high dosages of rifaximin are administered to treat SCD, then therapeutic efficacy is improved, but systemic exposure increases and gastrointestinal solubility remains limited
Solution Approach 1:
The patent changes the physical-chemical parameters of rifaximin by converting it from a solid crystalline form to an amorphous solid dispersion form. This parameter change increases gastrointestinal luminal solubility without requiring high dosages, thereby maintaining therapeutic efficacy while reducing the quantity of substance needed and minimizing systemic exposure
Solution Approach 2:
The patent creates a composite material system consisting of rifaximin dispersed in a polymer matrix (such as hydroxypropyl cellulose or polyvinylpyrrolidone). This composite structure allows the poorly soluble rifaximin to be delivered in a form that enhances solubility in the gastrointestinal tract, enabling effective treatment at lower dosages and reducing systemic exposure
2Reliability
If high dosages of rifaximin are administered, then therapeutic efficacy is improved, but gastrointestinal luminal solubility is still insufficient
Solution Approach 1:
The patent fundamentally changes the physical state of rifaximin from crystalline to amorphous, which dramatically improves gastrointestinal luminal solubility. This parameter change allows the drug to dissolve adequately in the GI tract at therapeutic dosages, resolving the contradiction between maintaining efficacy and achieving sufficient solubility
Solution Approach 2:
The patent introduces polymer excipients as intermediaries that facilitate the dissolution of rifaximin in the gastrointestinal tract. These polymers form a solubilizing matrix around the amorphous rifaximin particles, acting as a mediator that enhances luminal solubility and enables effective drug absorption at lower dosages
3Quantity of substance
If standard rifaximin formulations are used, then systemic exposure is achieved, but circulating aged neutrophils are not effectively reduced
Solution Approach 1:
The patent changes the dissolution rate parameter of rifaximin by using amorphous solid dispersion technology. This creates a controlled release profile that maintains adequate luminal concentrations for prolonged periods, effectively reducing circulating aged neutrophils even at lower systemic exposure levels. The modified release kinetics improve therapeutic reliability without requiring high systemic drug levels
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The described compositions provide clinical benefits in reducing vaso-occlusive crises and improving quality of life for SCD patients by effectively lowering circulating aged neutrophils with a lower dosage of rifaximin, minimizing systemic exposure and maximizing intestinal solubility.
Implementation Method 1
compositions comprising rifaximin, a hydrogenated castor oil, and at least one additional solubilizing excipient
Implementation Method 2
at least one additional solubilizing excipient
Data Source
AI summary
Pharmaceutical composition comprising rifaximin, a hydrogenated castor oil, and at least one additional solubilizing excipient for use in the treatment of sickle cell disease, vaso-occlusive crises or circulating ages neutrophils.